| Date |
Event |
Presentation |
Speakers |
|
April 6, 2010
|
IBCs 5th Annual China 2010 Pharmaceutical R&D Summit
|
1 Key Factors to be Considered for Clinical Development in Emerging Markets
|
Ruiping Dong
|
|
|
|
1 Chairperson's Opening Remarks
|
Ruiping Dong
|
|
January 26, 2009
|
Biomarker Assay Development
|
Moving Beyond Fit-for-Purpose: Use of Lean Practices to Accelerate Biomarker Assay Development
|
Russell S Weiner
|
|
|
|
Validation and Implementation of Flow Cytometric Assay to Evaluate Pharmacodynamic Biomarkers in Clinical Study
|
Dianna Wu
|
|
January 26, 2009
|
Translational Cancer Medicine
|
COMBINATION THERAPIES : Combination Approaches for the Treatment of Solid Tumors: Opportunities and Obstacles in the Era of Targeted Therapy
|
Jon M Wigginton
|
|
January 12, 2009
|
Model Based Drug Development
|
IN SILICO MODELING : Using Innovative Modeling and Simulation Strategies in the Development of Therapeutic Monocolonal Antibodies
|
Chee Ng
|
|
September 29, 2008
|
Genomic Biomarkers
|
Discovery of Gene Expression-Based Pharmacodynamic Biomarkers in Tumor Immunotherapies
|
Zenta Tsuchihashi
|
|
December 1, 2007
|
47TH American Socieity of Cell Biology
|
Post-Cytokinetic DNA Segregation by ATPases That Form DNA-Conducting Channels
|
Lois Burton
|
|
September 30, 2007
|
BioProcess International Conference & Exhibition
|
Production & Economics of Biopharmaceuticals, Strategies for Flexible Facility Design and Capacity Optimization (07:00 - 11:30)
|
Abhinav Shukla
|
|
|
|
Strategies for Flexible Facility Design and Capacity Optimization: Chairperson's Remarks
|
Abhinav Shukla
|
|
|
|
Market Forces and Technology Developments Affecting Economics of Biopharmaceuticals : Leveraging Contract Manufacturing as a Market Entry Strategy for Biologics
|
Abhinav Shukla
|
|
|
|
Production & Economics of Biopharmaceuticals ; Market Forces and Technology Developments Affecting Economics of Biopharmaceuticals (08:00 - 11:30)
|
Abhinav Shukla
|
|
|
|
Plenary Session : Keynote Presentations and Featured Discussion (14:00 - 18:00)
|
Abhinav Shukla, Tobias Massa
|
|
|
|
Plenary Session ; Keynote Presentations and Featured Discussion : Industry Expectations of the New Pharmaceutical Quality Assessment System
|
Tobias Massa
|
|
|
|
Plenary Session ; Keynote Presentations and Featured Discussion : Interactive Panel Discussion on the Future of Downstream Processing: How Best to Handle Higher Bioreactor Outputs and Greater Product Demands
|
Abhinav Shukla
|
|
September 17, 2007
|
Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19)
|
Third annual Genomic Biomarkers: PHARMACOGENETICS: Changing the Benefit/Risk Profile Using Pharmacogenetics (09:05-09:35)
|
Koustubh Ranade
|
|
|
|
Third annual Genomic Biomarkers: PHARMACOGENETICS (08:30-11:30)
|
Koustubh Ranade
|
|
|
|
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS: Discovery and Validation of Biomarkers Affected by Brivanib and Erbitux (11:30-12:00)
|
J. Suso Platero
|
|
|
|
Third annual Genomic Biomarkers: VALIDATION OF GENOMIC BIOMARKERS (11:30-14:00)
|
J. Suso Platero
|
|
June 23, 2007
|
Mechanism and Regulation of Prokaryotic Transcription
|
“DNA translocation and transcription-coupled DNA repair”
|
Nigel Savery
|
How We Rank